# Innoviva share price today (Innoviva, Inc., INVA)

> Innoviva, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. INVA · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/inva

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting better, from the last 12 quarters
- Price: $19.24 (−7.8% in a year)
- P/E: 7.6×, over 1 year
- Revenue (Jun 2026): $120 M (+19.3% on a year ago)
- Profit (Jun 2026): −$83.4 M (−231.0% on a year ago)
- Operating margin: 43.3% (−5.7 points on a year ago)
- ROE: 23%, FY25
- ROIC: 16.3%, against a 6.1% cost of capital: +10.2 points

The main question: yearly earnings per share moved +811.8% while the share price moved −7.8%. ## What is the Innoviva share price today? Innoviva, Inc.'s share price was $19.24 at the close on 5 November 2026. That is 12.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between $19 and $24, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 27 weeks running. Over the last 1 year the share price moved +3% while the S&P 500 moved +18%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 1 May 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Innoviva pay? Innoviva, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Innoviva on? Innoviva is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Innoviva profitable? Innoviva, Inc. posted a net loss of $83.4 M in the Jun 2026 quarter. Full-year FY25 profit was $271 M. Over 4 years profit has grown 0.5% a year on average. That loss is 69.8% of the quarter's revenue. The same quarter a year earlier earned $63.7 M. 3 of the last 12 reported quarters were loss-making. Jun 2026 profit was −$83.4 M, −231.0% on a year earlier. For the full year, FY25 profit was $271 M (+1,059.2% on the year before). Why profit moved: revenue changed +19.3% on a year earlier and the margin moved −5.7 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +2,596.1% and revenue +18.8%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Innoviva make, and is it growing? Innoviva, Inc. reported $120 M of revenue in the Jun 2026 quarter, +19.3% on the same quarter a year earlier. That is the 11th quarter in a row with growth on the year before. Over 4 years it has grown 1.2% a year on average. The last full year, FY25, came in at $411 M. The last four reported quarters add to $440 M. FY25 revenue was $411 M, +14.7% on the year before. Recent pace: the last four quarters grew +18.8% on average, against 1.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +18.8%, against +15.4% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +824.3%, against +56.7% a year (accelerating). ## How much of every $100 of sales does Innoviva keep? Innoviva, Inc.'s operating margin was 43.3% in the Jun 2026 quarter, 5.7 percentage points lower than the same quarter a year ago. Across 5 years it has been between 41.0% and 95.7%. The latest quarter is within that range. Why the margin moved: operating margin changed −5.7 percentage points on the year while gross margin changed −7.7 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Innoviva's profit turning into cash? Over the last 3 years, 111% of Innoviva, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $197 M of operating cash against $271 M of profit. After $1.1 M of spending on assets, $196 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Innoviva's cash go? Innoviva, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.8 M on assets over the last 3 years. Averaged over those years that is 0.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.8 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Innoviva's P/E ratio, and how does it compare with its own history? Innoviva, Inc.'s P/E is 7.6×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +811.8% while the price moved −7.8%. Earnings did better than the price, which pulled the multiple down within its own range. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Innoviva business getting better or worse? Innoviva, Inc.'s business is getting better. Profit growth hit its low 5 quarters ago at −87.0% and has recovered to +824.3%, with ROCE steady at 14.5%. This is based on 12 quarters of 4 measures. Why it matters: a lasting rise from a low is what this page is built to show. ## How much does Innoviva earn on its capital? Innoviva, Inc. earned a ROE of 23% in FY25. That is up from a low of 3% in FY24. Its return on capital used (ROIC) is 10.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 65.9% net margin and 0.25× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 65.9% net margin × 0.25× asset turnover × 1.39× leverage (assets divided by equity) ≈ 22.9% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 16.3% − 6.1% = +10.2 percentage points. The 6.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. ## Does Innoviva have too much debt? Innoviva, Inc. has total debt of $331 M against shareholder equity of $1.2 B as of Jun 2026, so its debt is 0.27× its equity, which is very little. Year by year, that ratio went from 0.75 in FY21 to 0.28 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Innoviva shareholding pattern? 10.7% of Innoviva, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 7.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Innoviva from balance-sheet trouble? For Innoviva, Inc., the Z-score is 3.27. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 3.27 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Innoviva rank in its industry? There is no score against its industry: Innoviva, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Innoviva compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Innoviva in size? Innoviva is the 98th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: uniQure N.V., Ascentage Pharma Group International and Ocular Therapeutix, Inc. Just below it: AnaptysBio, Inc., Taysha Gene Therapies, Inc. and UroGen Pharma. ### Biotechnology companies close in size

1. [uniQure N.V.](https://www.sectoralpha.in/us/stocks/qure) $1.5 billion
2. [Ascentage Pharma Group International](https://www.sectoralpha.in/us/stocks/aapg) $1.4 billion
3. [Ocular Therapeutix, Inc.](https://www.sectoralpha.in/us/stocks/ocul) $1.4 billion
4. Innoviva, Inc. $1.4 billion
5. [AnaptysBio, Inc.](https://www.sectoralpha.in/us/stocks/anab) $1.4 billion
6. [Taysha Gene Therapies, Inc.](https://www.sectoralpha.in/us/stocks/tsha) $1.3 billion
7. [UroGen Pharma Ltd.](https://www.sectoralpha.in/us/stocks/urgn) $1.3 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [The Pennant Group, Inc.](https://www.sectoralpha.in/us/stocks/pntg) $1.5 billion · Medical Care Facilities
2. [CBL & Associates Properties, Inc.](https://www.sectoralpha.in/us/stocks/cbl) $1.5 billion · REIT - Retail
3. Innoviva, Inc. $1.5 billion
4. [ANI Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/anip) $1.5 billion · Drug Manufacturers - Specialty & Generic
5. [Nanobiotix S.A.](https://www.sectoralpha.in/us/stocks/nbtx) $1.5 billion · Biotechnology

## What else do people ask about Innoviva? ### What were Innoviva's latest quarterly results? Innoviva, Inc. reported revenue of $120 M and a net loss of $83.4 M for the Jun 2026 quarter. Revenue rose 19.3% and profit fell 231.0% compared with a year earlier. Earnings per share were −$1.14. The operating margin was 43.3%, 5.7 percentage points lower than a year earlier (as of 5 November 2026). ### What is Innoviva's market cap? Innoviva, Inc.'s market capitalisation is $1.4 B at a stock price of $19.24. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Innoviva performing? Innoviva, Inc.'s latest readings are below. In its latest quarter, revenue rose 19.3% and profit fell 231.0% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 27 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Innoviva's stock price go up? This page does not forecast Innoviva, Inc.'s stock price. What it shows instead: the stock price is $19.24. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Is Innoviva's profit real cash? Yes, over the last 3 years, 111% of Innoviva, Inc.'s reported profit came in as cash from operations. The latest year was lower at 73%, so the trend is worth watching. In FY25, operating cash was $197 M against reported profit of $271 M. Most of that cash then goes into building new capacity. These are yearly figures (as of 5 November 2026). ### Where is Innoviva in its business cycle? Innoviva, Inc.'s FY25 operating margin was 41.0%, against a 5-year range of 41.0% to 95.7%: the low end of its own range, which is often where recoveries start. The latest quarter was 43.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Innoviva story? The main question: yearly earnings per share moved +811.8% while the share price moved −7.8%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Innoviva a stock worth studying right now? What the numbers show: Innoviva, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.